Author(s): Rolfs, Prof. Arndt, MD, Tanislav, Prof. Christian, MD, Schneider, Christian, Roller, Fritz, Dr., Fuest, Sven, Meyer, Marco, Harth, Sebastian, Dr., Gündüz, Dursun, MD, Krombach, Gabriele Anja, Bauer, Pascal
Mass-spectrometry based quantification of biomarkers is a routine step in the diagnostic workup of many diseases at CENTOGENE. Read more about our recent research.
Mass-spectrometry based quantification of biomarkers is a routine step in the diagnostic workup of many diseases at CENTOGENE. In addition, these well-established tools are increasingly being utilized in research settings. A recent example involved the Fabry Disease (FD)-specific biomarker Lyso-Gb3. Scientists including CENTOGENE’s CEO Prof. A. Rolfs showed that sub-clinical cardiac involvement in FD is accurately reflected by plasma-based Lyso-Gb3 values.
Read publication
